Are you Dr. Curiel?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 61 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1 Medical Center Dr
Lebanon, NH 03756Phone+1 603-650-5747Fax+1 210-257-1428- Is this information wrong?
Summary
- Dr. Tyler Curiel, MD is an oncologist in Lebanon, New Hampshire. He is currently licensed to practice medicine in New Hampshire, Louisiana, and Texas. He is affiliated with Audie L. Murphy Memorial Veterans' Hospital, Methodist Hospital, and St Lukes Baptist Hospital.
Education & Training
University of ColoradoFellowship, Hematology and Medical Oncology, 1995 - 1997
Massachusetts General HospitalResidency, Internal Medicine, 1986 - 1990
Yale-New Haven Medical CenterInternship, Internal Medicine, 1985 - 1986
Duke University School of MedicineClass of 1982
Certifications & Licensure
CO State Medical License 1991 - 2025
TX State Medical License 2000 - 2024
NH State Medical License 2022 - 2024
LA State Medical License 2001 - 2008
CT State Medical License 1985 - 1987- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer Start of enrollment: 2007 Feb 01
- Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors Start of enrollment: 2012 Jun 01
- A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer Start of enrollment: 2009 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1...Haiyan Bai, Alvaro S Padron, Yilun Deng, Yiji J Liao, Clare J Murray, Carlos Ontiveros, Suresh J Kari, Aravind Kancharla, Anand V R Kornepati, Myrna Garcia, Ryan Micha...> ;Journal for Immunotherapy of Cancer. 2023 Feb 1
- 3 citationsPRC2-Mediated Epigenetic Suppression of Type I IFN-STAT2 Signaling Impairs Antitumor Immunity in Luminal Breast Cancer.Juyeong Hong, Ji Hoon Lee, Zhao Zhang, Yanming Wu, Mei Yang, Yiji Liao, Richard de la Rosa, Jessica Scheirer, Douglas Pechacek, Nu Zhang, Zhenming Xu, Tyler Curiel, Xi...> ;Cancer Research. 2022 Dec 16
- 1 citationsSelective delipidation of Mycobacterium bovis BCG retains antitumor efficacy against non-muscle invasive bladder cancer.Niannian Ji, Meijun Long, Andreu Garcia-Vilanova, Russell Ault, Juan I Moliva, Kizil A Yusoof, Neelam Mukherjee, Tyler J Curiel, Hong Dixon, Jordi B Torrelles, Robert ...> ;Cancer Immunology, Immunotherapy. 2023 Jan 1
- Join now to see all
Press Mentions
- Suppressive IL-17A+Foxp3+ and Ex-Th17 IL-17AnegFoxp3+ Treg Cells Are a Source of Tumour-Associated Treg CellsMarch 14th, 2020
Chutes & Ladders—Biogen Executive Kress Takes over the Reins of SyntimmuneJanuary 5th, 2018
Agenus Announces Key Leadership to Advance Combination Trials for Planned BLA FilingsJanuary 4th, 2018
Grant Support
- Senior LeadershipNational Cancer Institute2009–2011
- Planning And EvaluationNational Cancer Institute2009–2011
- DevelopmentalNational Cancer Institute2009–2011
- Career DevelopmentNational Cancer Institute2009–2011
- Cancer Prevention And Population SciencesNational Cancer Institute2009–2011
- AntibodyNational Cancer Institute2009–2011
- AdministrationNational Cancer Institute2009–2011
- Phase II Trial Of Ontak To Treat Ovarian Cancer Under B*Food And Drug Administration2007–2010
- A Novel MAPK Family In T. GondiiNational Institute Of Allergy And Infectious Diseases2006–2010
- Plasmacytoid Dendritic Cell Behavior In Ovarian CancerNational Cancer Institute2007–2009
- CXCR4/SDF-1 Interactions In Ovarian Cancer PathogenesisNational Cancer Institute2007
- SAN Antonio Cancer InstituteNational Cancer Institute2005–2007
- A Phase II Trial Of Intravenous Ontak To Treat Epithelial Ovarian Cancer FIGONational Center For Research Resources2006
- Phase II Trial Of Ontak To Treat Ovarian Cancer Under B*Food And Drug Administration2006
- A Novel MAPK Family In T. GondiiNational Institute Of Allergy And Infectious Diseases2005–2006
- Plasmacytoid Dendritic Cell Behavior In Ovarian CancerNational Cancer Institute2005–2006
- Phase I/II Dose De-Escalation Trial Of Intravenous Ontak In Patients With CancerNational Center For Research Resources2004–2006
- CXCR4/SDF-1 Interactions In Ovarian Cancer PathogenesisNational Cancer Institute2004–2006
- Dendritic Cell-Mediated Anti-Tumor ImmunityNational Center For Research Resources2003–2006
- Targeting SIV Nef Directly To Dendritic CellsNational Center For Research Resources2005
- Dendritic Cell Targeted Hepatitis C Virus ImmunotherapyNational Institute On Drug Abuse2003
- Dc-Induced Hiv-Specific T Cell ImmunityNational Institute Of Allergy And Infectious Diseases2001
- Dc-Induced Hiv-Specific T Cell ImmunityNational Institute Of Allergy And Infectious Diseases2000–2001
- Human Cellular Immunity To Toxoplasma GondiiNational Institute Of Allergy And Infectious Diseases1997–1999
- Human Cellular Immunity To Toxoplasma GondiiNational Institute Of Allergy And Infectious Diseases1995–1996
- SCID Mouse And Human Stem Cell CoreNational Institute Of Allergy And Infectious Diseases1994–1995
- Cellular Immunity In AIDSNational Institute Of Allergy And Infectious Diseases1988–1989
Hospital Affiliations
Audie L. Murphy Memorial Veterans' HospitalSan Antonio, Texas
Methodist HospitalSan Antonio, Texas- St Lukes Baptist HospitalSan Antonio, Texas
University Health / UT Health Science Center at San AntonioSan Antonio, Texas
